|
|
|
| home > directory > CMAB Biopharma |
|
|
 PHARMACEUTICAL INDUSTRY DIRECTORY |
CMAB Biopharma |
 |
| |
|
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.
Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.
Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 175 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.
At CMAB Biopharma, we currently provide expertise and experience in cell line development, process and analytical development, drug substance (DS) CGMP manufacturing as well as fully automated aseptic fill / finish along with lyophilisation. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer unit for protein characterisation. Our four parallel upstream suites offer flexible CGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. Finally, we can provide our clients with lot release testing and standardised stability studies.
Our operational protocols and quality standards comply fully with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce CGMP material for both domestic as well as global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.
To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com/en or write to us at hello@cmabbio.com. We look forward to hearing from you.
|
|
|
|
|
|
| |
|
|
|
|
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
 |
News and Press Releases |
 |
Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration
Philadelphia, PA – November 14, 2019: Signant Health,
formerly CRF Health and Bracket, is proud to announce that it has integrated
its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system.
The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of
collecting and monitoring real-world activity, mobility, and sleep outcomes
data for patients and researchers.
More info >> |
|
|
|
